Clinical Report: HPV-Specific Testing in Throat Cancer

Overview

A survey of head and neck pathologists in the UK and Ireland indicates limited in-house access to HPV-specific testing for oropharyngeal squamous cell carcinoma, with significant variability in practice. Barriers such as cost and turnaround times persist.

Background

Oropharyngeal squamous cell carcinoma (OPSCC) has distinct clinical subtypes, notably HPV-associated and HPV-independent, which have differing prognoses. Accurate HPV status determination is crucial for treatment decisions and patient outcomes. The current reliance on P16 immunohistochemistry as a surrogate marker raises questions about the standardization and accessibility of HPV-specific testing.

Data Highlights

Key Findings

• 100% of surveyed pathologists had access to P16 immunohistochemistry in-house.
• 91% reported access to HPV-specific testing, primarily PCR.
• Only 25% had in-house access to HPV-specific testing.
• The median turnaround time for HPV-specific testing was 14 days, compared to 2 days for P16 immunohistochemistry.
• 36% of pathologists requested HPV-specific testing based on clinical suspicion.
• Barriers to HPV-specific testing include cost and turnaround times.

Clinical Implications

The findings highlight the need for improved access to HPV-specific testing in clinical practice to enhance diagnostic accuracy. Addressing the barriers related to cost and turnaround times is essential for standardizing patient pathways in the management of OPSCC.

Conclusion

The variability in HPV-specific testing practices across the UK and Ireland underscores the necessity for efforts to standardize testing and improve accessibility in order to optimize patient care.

Related Resources & Content

1. MDSpire News, HPV Testing Guidelines Updated for Head and Neck Carcinomas, 2025 -- Updated guidelines for HPV testing.
2. Keck Medicine of USC, Will Circulating Tumor DNA Help Predict HPV-Related Throat Cancer?, 2025 -- Discussion on circulating HPV DNA as a biomarker.
3. The Pathologist, HPV Testing Guidelines Updated for Head and Neck Carcinomas, 2025 -- Overview of updated HPV testing guidelines.
4. CAP, Human Papillomavirus Testing In Head And Neck Carcinomas, 2025 -- CAP guidelines on HPV testing.
5. MDSpire News — HPV Testing Guidelines Updated for Head and Neck Carcinomas
6. the pathologist — HPV Testing Guidelines Updated for Head and Neck Carcinomas
7. Frontiers in Immunology — HPV-specific innovations and controversies in therapeutic strategies for HPV-associated oropharyngeal carcinoma
8. Human Papillomavirus Testing In Head And Neck Carcinomas - CAP
9. https://www.rcpath.org/asset/24D6FA0D-7462-4876-AB5D826E8104DDEE/
10. Radiotherapy plus cetuximab or cisplatin for human papillomavirus (HPV)-positive oropharyngeal cancer: a randomized, multicenter, non-inferiority clinical trial - PMC